These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27560967)

  • 1. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
    Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
    PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
    Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.
    Vinding NE; Staerk L; Gislason GH; Torp-Pedersen C; Bonde AN; Rørth R; Lee CJ; Olesen JB; Køber L; Fosbøl EL
    Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):20-30. PubMed ID: 31730151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
    Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
    Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
    Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
    Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
    Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
    Blin P; Dureau-Pournin C; Cottin Y; Bénichou J; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
    Br J Clin Pharmacol; 2019 Feb; 85(2):432-441. PubMed ID: 30423205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
    Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
    Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
    Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
    Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
    Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
    Russo V; Bianchi V; Cavallaro C; Vecchione F; De Vivo S; Santangelo L; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
    Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.